ZA202102494B - New combination solution for treating chemotherapy refractory cancer - Google Patents

New combination solution for treating chemotherapy refractory cancer

Info

Publication number
ZA202102494B
ZA202102494B ZA2021/02494A ZA202102494A ZA202102494B ZA 202102494 B ZA202102494 B ZA 202102494B ZA 2021/02494 A ZA2021/02494 A ZA 2021/02494A ZA 202102494 A ZA202102494 A ZA 202102494A ZA 202102494 B ZA202102494 B ZA 202102494B
Authority
ZA
South Africa
Prior art keywords
new combination
combination solution
refractory cancer
treating chemotherapy
chemotherapy refractory
Prior art date
Application number
ZA2021/02494A
Other languages
English (en)
Inventor
J Li Chiang
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Publication of ZA202102494B publication Critical patent/ZA202102494B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2021/02494A 2018-10-12 2021-04-15 New combination solution for treating chemotherapy refractory cancer ZA202102494B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811195239 2018-10-12
PCT/CN2019/110904 WO2020074010A1 (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Publications (1)

Publication Number Publication Date
ZA202102494B true ZA202102494B (en) 2023-01-25

Family

ID=70163618

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/02494A ZA202102494B (en) 2018-10-12 2021-04-15 New combination solution for treating chemotherapy refractory cancer

Country Status (16)

Country Link
US (2) US12257227B2 (cg-RX-API-DMAC7.html)
EP (1) EP3865130A4 (cg-RX-API-DMAC7.html)
JP (2) JP7513286B2 (cg-RX-API-DMAC7.html)
KR (1) KR102960038B1 (cg-RX-API-DMAC7.html)
CN (2) CN120168498A (cg-RX-API-DMAC7.html)
AU (1) AU2019357933B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006898A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115869A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190771A1 (cg-RX-API-DMAC7.html)
IL (1) IL282228B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004151A (cg-RX-API-DMAC7.html)
PH (1) PH12021550815A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103707TA (cg-RX-API-DMAC7.html)
TW (1) TWI848990B (cg-RX-API-DMAC7.html)
WO (1) WO2020074010A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102494B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004151A (es) * 2018-10-12 2021-09-08 1Globe Biomedical Co Ltd Nueva solución de combinación para el tratamiento contra cáncer refractario a la quimioterapia.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
DK2547205T3 (da) 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
NZ602328A (en) 2010-03-19 2014-11-28 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
CN103402993A (zh) 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4,9-二羟基-萘并[2,3-b] 呋喃新型酯
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
JP2018511643A (ja) * 2015-04-17 2018-04-26 ボストン バイオメディカル, インコーポレイテッド 癌を治療するための方法
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CN107766371B (zh) * 2016-08-19 2023-11-17 中兴通讯股份有限公司 一种文本信息分类方法及其装置
MX2021004151A (es) * 2018-10-12 2021-09-08 1Globe Biomedical Co Ltd Nueva solución de combinación para el tratamiento contra cáncer refractario a la quimioterapia.

Also Published As

Publication number Publication date
KR102960038B1 (ko) 2026-04-30
IL282228A (en) 2021-05-31
US20210393571A1 (en) 2021-12-23
AU2019357933A1 (en) 2021-05-20
PH12021550815A1 (en) 2021-10-04
EA202190771A1 (ru) 2021-09-07
TWI848990B (zh) 2024-07-21
BR112021006898A2 (pt) 2021-07-20
CN113164438B (zh) 2025-03-18
US12257227B2 (en) 2025-03-25
JP2024123152A (ja) 2024-09-10
US20250235425A1 (en) 2025-07-24
TW202027738A (zh) 2020-08-01
EP3865130A4 (en) 2022-07-20
JP2022504760A (ja) 2022-01-13
KR20210076951A (ko) 2021-06-24
MX2021004151A (es) 2021-09-08
SG11202103707TA (en) 2021-05-28
JP7513286B2 (ja) 2024-07-09
CN113164438A (zh) 2021-07-23
CN120168498A (zh) 2025-06-20
EP3865130A1 (en) 2021-08-18
IL282228B1 (en) 2026-07-01
CA3115869A1 (en) 2020-04-16
WO2020074010A1 (zh) 2020-04-16
AU2019357933B2 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
IL270720A (en) Combination of treatments for cancer treatment
IL287907A (en) Cancer treatment methods
IL273395A (en) Combined therapies for cancer treatment
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PT3431105T (pt) Composição medicinal para tratamento de cancro
IL263497B (en) 1-tetrahydropyranylcarbonyl-3,2-dihydro-h1-indole compounds for cancer treatment
IL255060A0 (en) Combined treatment for cancer
IL254705B (en) Combined treatment for cancer
LT3377516T (lt) Kompozicija vėžiui gydyti
IL253573A0 (en) Combined therapies for the treatment of cancers
IL282093B1 (en) Combination therapy for cancer
EP3892282A4 (en) COMBINATIONS FOR TREATING CANCER
GB201709405D0 (en) Compounds for treating ovarian cancer
HUE050567T2 (hu) Triciklusos heterociklusok rák kezelésére
IL255022A0 (en) Cancer treatment methods
IL270820A (en) Antisense therapies for cancer treatment
IL268416A (en) Pharmaceutical combinations for cancer treatment
SG11202010528XA (en) Combinations for treating cancer
GB201909468D0 (en) Compounds for treating cancer
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
PL3296294T3 (pl) Związek do leczenia lub zapobiegania nowotworowi piersi
SG11202103707TA (en) New combination solution for treating chemotherapy refractory cancer
ZA201900438B (en) Combination therapies for treating cancer
IL278921A (en) Combined treatments for cancer
GB201703907D0 (en) Novel therapies for cancer